



Phone: 1-833-453-7362 Fax: 1-833-770-7017 M-F: 8 AM-8 PM ET

Patient's name		OOB (MM/DD/YYYY)
Prescribers to complete pages 1-5, pages 1-5	atient to complete pages 6–11, or enroll digitally at	LEQEMBIEnrollment.com.
ଠ Program Offerings	Physician to select from the following program offe	erings to enroll
Eisai Patient Support (EPS) offerings EPS offers information and resources to help Provider: Complete all sections. Sign pages Patient: Complete and sign pages 6–11.		
Benefits investigation Helps patients understand their coverage for LEQEMBI.	Copay Assistance Program Helps eligible commercially insured patients with their LEQEMBI cost.	Patient Assistance Program (PAP) Provides LEQEMBI at no cost to eligible patients with financial need. Valid prescription required; see pharmacy information on page 3.
LEQEMBI IQLIK™ Injection Support Offerings Reminder: LEQEMBI IQLIK injection support of	ferings are ONLY available to patients on IQLIK Su	ocutaneous (SubQ) Maintenance treatment.
LEQEMBI IQLIK Welcome Kit • Demo Autoinjector Kit • Folder with educational resource Patient: Complete and sign pages 6-1	Patients presinjection suppresidents *Nurse Educators LEQEMBI) and design of the suppresident in the suppression in the suppressident in the suppression i	injection support cribed LEQEMBI IQLIK may access one-on-one port either in-person or virtually. It is are provided by Eisai and Biogen (manufacturers of it is not work under the direction of your healthcare provider. In the provided of the direction of the provider of
ଠ Prescriber Information	On Completion required regardless of program	offering selection
Prescriber's first name [†]	Prescriber's last name [†]	
Prescriber's title	If NP or PA, under direc	tion of doctor
Prescriber's NPI†	Medicare PTAN [†]	Tax ID [†]
Office address [†]	City [†]	State [†] ZIP [†]
Office phone [†]	Office fax	
Office contact and title		Office contact phone
Office contact email		
Healthcare organization name		





Phone: 1-833-453-7362 | Fax: 1-833-770-7017 | M-F: 8 AM-8 PM ET

Patient's name			DOB (MM/DD/Y	YYY)
O শ্রে	mation Comple Welcon	etion required for all progra ne Kit	ım offerings except the l	LEQEMBI Companion
☐ LEQEMBI Infusion Initiation*† ☐	LEQEMBI Infusion Maint	enance* [†] LEQEMBII	QLIK SubQ Maintenance*†	
Primary ICD-10 code*		Secondary ICD-	0 code	
Select procurement method below. If s			ide preferred pharmacy.	
Preferred pharmacy		Phone*	Fa	ax
O സ്രീ Infusion Site Info	ormation co	mpletion only required for	_EQEMBI Infusion patien	ts
Do you require assistance in locating a If you have selected No above and you	•		No t site, please fill out the	information below:
Name of infusion site or healthcare pro	ovider*			
Street address*				
City*		State*	ZIP* _	
Office contact and title*				
Phone*		Fax		
Treatment site NPI*		Treatment sit	e tax ID*	
ଠ ଜ୍ୟା Insurance Inform	mation			
Is the patient insured?] No			
If insured, please fill out the informatio	n below or attach a co	ppy of the front and back o	f the patient's insurance	e card(s).
Is prior authorization in place with infu	sion provider?	s Auth #		No
	Primary Insura	ance Secon	dary Insurance	Pharmacy Benefit
Insurance name				
Subscriber name (if not patient)				
Subscriber DOB (MM/DD/YYYY)				
Subscriber/Policy ID #				
Group #				
Insurance phone				

^{*}Required field.

[†]Prescriber: Please attach a separate prescription if this section does not comply with your state's prescription law.





Phone: 1-833-453-7362 | Fax: 1-833-770-7017 | M-F: 8 AM-8 PM ET

DOR (MM/DD/YYYY)

atient's name		DOE	3 (MM/DD/YYYY)
୍ଦି Prescription Info	ormation for LEQEI	MBI*	
Patient's first name [†]		Patient's last name [†]	
DOB (MM/DD/YYYY)†	Known drug allergie	s	NKDA
Patient's weight (lbs) ^{†‡}	Concurrent medicat	ions	
Prescriber name (First, Last)		Pres	criber phone
Prescriber address		Pres	criber's NPI [†]
LEQEMBI Infusion Therapy (lecanemak	o-irmb 100 mg/mL)		
Infuse 10 mg/kg intravenously over 60	minutes every weeks	s. 28-day supply	
Refills			
LEQEMBI IQLIK Subcutaneous Injectio	n (360 mg/1.8 mL single dose)		
Inject 360 mg subcutaneously once a v	veek. (4 pens) 28-day supply		
Refills			
0	_		
Communication	Preferences		
Primary case contact? Prescribe	er Infusion site Preferr	ed communication method?	Fax only Fax and phone updates
Fax communications to be sent to:	☐ Infusion site only ☐ Presci	riber only 🔲 Both	
Healthcare Provider Attesta	ation and Concont		
		state of licensure to prescrib	e LEQEMBI. I certify that the information
	account relevant patient safety	considerations and the full	prescribing information. By enrolling my
eatient in this Program, I agree that I may	be contacted by Eisai's Medica	I team to receive educations	al information regarding LEQEMBI.
Prescriber certification†			Date [†]
(ORIGINAL SIGNATURE REQUIRED)			
Pharmacy Information	n		
HCPs can send prescriptions to the fol	lowing pharmacy electronically o	r via fax. Required for PAP ar	nd LEQEMBI Infusion TSP evaluation only.
Eisai Patient Support Pharma	су		
2730 S. Edmonds Lane, Suite 400A, L NCPDP: 5942176 NPI: 1861259194		Hours of operation: M-F 9 AM-6 PM ET	
NOFDF: 3342170 NFI: 1001233134	1 a.s. 1 000 770 7017	MILE A WIN O AW E I	

Eisai Patient Support Pharmacy is operated by Sonexus™ Health Pharmacy Services, LLC.

^{*}Prescriber: Please attach a separate prescription if this section does not comply with your state's prescription law. †Required field.

^{*}LEQEMBI is dosed based on patient's actual weight.





Phone: 1-833-453-7362 Fax: 1-833-770-7017 M-F: 8 AM-8 PM ET

Patient's name	DOB (MM/DD/YYYY)

LEQEMBI Infusion Temporary Supply Program terms and conditions

The Temporary Supply Program provides a temporary free supply of up to 75 days of LEQEMBI infusions for eligible, commercially insured patients new to LEQEMBI therapy awaiting a final coverage determination from their insurance provider for 5 or more business days and the patient's provider has submitted a first-level appeal of the prior authorization denial. Patient must have a valid prescription for LEQEMBI infusion for an FDA-approved indication and meet certain financial need criteria. Not available for uninsured patients or patients enrolled in state and federal healthcare programs, including Medicare, Medicaid, Medigap, VA, DoD, or TRICARE. Eisai reserves the right to rescind, revoke, or amend this Program at any time without notice. Please see complete terms and conditions, and full Prescribing Information at EisaiPatientSupport.com/LEQEMBI.

LEQEMBI Patient Assistance Program terms and conditions

The Patient Assistance Program for LEQEMBI provides free drug for eligible patients who meet financial need and insurance coverage criteria. Patient must have a valid prescription for LEQEMBI for an FDA-approved indication. Eisai reserves the right to rescind, revoke, or amend this Program at any time without notice. Please see complete terms and conditions, and full Prescribing Information at EisaiPatientSupport.com/LEQEMBI.

LEQEMBI Copay Assistance Program terms and conditions

Patient must be prescribed LEQEMBI for an FDA-approved indication and have private, commercial health insurance that provides coverage for LEQEMBI. The offer is not valid for patients enrolled in state and federal healthcare programs, including Medicare, Medicaid, Medigap, VA, DoD, or TRICARE, that cover outpatient care, including for physician-administered or prescription drugs, or otherwise cover LEQEMBI. The offer is not valid for uninsured or self-paying patients, or for LEQEMBI treatments reimbursed in full by any third-party payer. Eligible patients who participate in the Program may pay as little as \$0 out-of-pocket per date of treatment. Eisai Inc. will pay up to \$10,000 per calendar year toward an eligible patient's out-of-pocket costs for LEQEMBI, including deductibles, copays, and coinsurances. Depending on the patient's insurance plan, the patient could have additional financial liability for any amount over Eisai's maximum benefit.

Additional Copay Assistance Program terms and conditions for LEQEMBI Infusion: Supporting documentation, including a CMS-1500 or UB-04 form and an insurance explanation of benefits (EOB) with itemized charges that include the billing code for LEQEMBI, must be submitted to the LEQEMBI Copay Assistance Program within 365 days of the date of treatment or the request will be rejected.

Please see complete terms and conditions on pages 10-11 of this form, and full Prescribing Information at EisaiPatientSupport.com/LEQEMBI.





Phone: 1-833-453-7362 | Fax: 1-833-770-7017 | M-F: 8 AM-8 PM ET

Patient's name	DOB (MM/DD/YYYY)
LEQEMBI Patient Assistance, Temporary Supp Healthcare provider attestation	oly, and Copay Assistance Programs:
conditions set forth in this enrollment form and also available at Eisal by Eisai under the Patient Assistance Program and the Temporary Su at no cost to the eligible, enrolled patient named on this form for an I transferred, returned for credit, or submitted to any third party (inclu reimbursement. I certify that I will maintain free LEQEMBI received for the LEQEMBI only to the enrolled patient named on this form, and dis	ry Supply Program and LEQEMBI Patient Assistance Program terms and iPatientSupport.com/LEQEMBI. I certify that any medications supplied upply Program (together, the "Programs"), as applicable, will be provided FDA-approved indication only and shall not be sold, traded, bartered, ding federal healthcare programs such as Medicare and Medicaid) for om the Programs separately from commercial inventory, administer scard unused amounts in open vials (as applicable). I understand that to the patient's home address entered on the enrollment form unless
patient is no longer on therapy or otherwise cannot use the LEQEMB Companion program to arrange for product return or disposal. I unde Inc. and the patient's and provider's continuing compliance with all el I agree to provide Eisai, or its authorized agent(s), access to the median continuing compliance with all el I agree to provide Eisai, or its authorized agent(s), access to the median continuing compliance with all el I agree to provide Eisai, or its authorized agent(s), access to the median continuing compliance with all el I agree to provide Eisai, or its authorized agent(s), access to the median continuing compliance with all el I agree to provide Eisai, or its authorized agent(s), access to the median continuing compliance with all el I agree to provide Eisai, or its authorized agent(s), access to the median continuing compliance with all el I agree to provide Eisai, or its authorized agent(s), access to the median continuing compliance with all el I agree to provide Eisai, or its authorized agent(s), access to the median continuing compliance with all el I agree to provide Eisai, or its authorized agent(s), access to the median continuing compliance with all el I agree to provide Eisai, or its authorized agent(s).	st receive all LEQEMBI doses through the Program only. If the enrolled I provided through the Programs, I agree to promptly contact the LEQEMBI extand eligibility under these Programs is subject to the approval of Eisai ligibility and Program requirements, as set by Eisai Inc. from time to time. dical, financial and insurance records that this patient has authorized (in rized representatives for the purposes of verifying the patient's eligibility rovided to him or her through the Programs.
forth in the LEQEMBI Copay Assistance Program terms and condition	the best of my knowledge, the patient meets the eligibility criteria set as. I understand patient participation in the LEQEMBI Copay Assistance the patient's and my continuing compliance with all LEQEMBI Copay ge the patient for the copay or coinsurance prior to treatment with
Prescriber signature*	 Date*

Patient must fill out pages 6-11 to complete the form

*Required field. Page 5 of 11





itient's name			DOB (MM/DD/YYY	Y)
Patient to complete pages 6-1 the exception of the LEQEMBI programs, you may sign the ad details with the LEQEMBI Compaccuracy, please contact at 1-8	IQLIK Welcome Kit and Nurseditional attestations to be concanion program to help you ge	e Educator offering. While your sidered for programs in the f	our signature is only uture. Your prescrib	required for the selected er has shared your insurance
LEQEMBI IQLIK Injection Support Of Reminder: LEQEMBI IQLIK injection so	•	ailable to patients on IQLIK S	Subcutaneous (SubC	Q) Maintenance treatment.
LEQEMBI IQLIK Welcome Kit This kit includes: * Demo Autoinjector Kit * Folder with educational resources	Nurse Educator* I would like to enroll in the COMPANION Nurse Education understand that if I elect to training, I agree to have a note to my home for the training training on a video call, on LEQEMBI COMPANION. *Nurse Educators are provided (manufacturers of LEQEMBI) at the direction of your healthcate. Yes, opt-in	LEQEMBI tor Program. I preceive the injection Nurse Educator come g, or to receive the a secure platform by	eminder: You must be ot in to Nurse Educato	atient Information section and
O Patient Informa	tion		ALL F	IELDS REQUIRED
Patient's name (First, Middle, Last) _		DOB (MM/DD/YYYY)		Sex Male Female
Address		City	State	Zip
Home phone	Cell phone	Email ad	ldress	
Alternate contact		Relationship	Phone	e number
Prescriber name (First, Last)			Prescriber phone	
Communication		gardless of your selection be via phone to confirm eligibil		
Preferred contact method: Home	e phone Cell phone	Email OK to leave a	message? 🔲 Ye	es No
		·		
Best time to call: Morning	Noon Evening			





Phone: 1-833-453-7362 | Fax: 1-833-770-7017 | M-F: 8 AM-8 PM ET

Patient's name	DOB (MM/DD/YYYY)
Collection, use, and disclosure of health information	
As part of the LEQEMBI Companion program for LEQEMBI (the "Program"), Eisai, its affiliates,	vendors, agents, collaboration partners, and

As part of the LEQEMBI Companion program for LEQEMBI (the "Program"), Eisai, its affiliates, vendors, agents, collaboration partners, and representatives supporting the Program (collectively, "Eisai") collect certain personal information about you, including but not limited to information about your health condition, diagnoses, treatment, insurance coverage, contact information and address, Social Security number, payment, name and other identifiers, etc. (collectively, "Health Information"). Please review the below disclosures of how that information will be processed under certain circumstances and the related authorizations or consents for those situations.

Consent for Eisai to process your health information

Eisai collects, uses, and discloses (collectively, "Process") your Health Information as necessary to provide you the support offerings in our Program. If you choose not to provide this information, we cannot provide our support offerings. For more information on our data processing practices and rights you may have, please see our Privacy Policy at https://us.eisai.com/privacy-policy. If you or your healthcare provider provide Health Information and later change your mind, you may withdraw your consent for future processing or request deletion of your information (subject to applicable law) at any time by contacting the Program at 2730 S. Edmonds Lane, Suite 300, Lewisville, TX 75067, faxing a request to 1-833-770-7017, or calling 1-833-453-7362. By signing below, I consent to Eisai Processing my Health Information.

Name of patient	Patient signature	Date
Name of authorized representative	Authorized representative signature	Date
	Relation to patient	

30

Authorization for Use and Disclosure of Health Information

Each of your physicians, infusion sites, pharmacists, and other healthcare providers (together, "Healthcare Providers"), as well as each of your health insurers ("Insurers"), may need to use or disclose your Health Information to Eisai (as defined above) so that the LEQEMBI Companion program for LEQEMBI (the "Program") may use the information to provide you with the support offerings ("offerings") below:

- Process your enrollment (or re-enrollment, as applicable) and determine eligibility for the Program's financial assistance, copay assistance, and temporary supply support offerings, including benefit verifications and prior authorizations support;
- II. Provide you with the Program's online support, financial assistance offerings, and copay assistance support offerings;
- III. Verify, investigate, coordinate, and communicate with your Healthcare Providers and Insurers about your insurance benefits and coverage, and your medical care and prescribed medication;
- IV. Facilitate dispensing of your prescription by a non-commercial Pharmacy;
- V. Provide you with disease management and other educational materials, information, and support offerings related to your treatment experience with your prescribed medication and condition;





Phone: 1-833-453-7362 | Fax: 1-833-770-7017 | M-F: 8 AM-8 PM ET

Patient's name	DOB (MM/DD/YYYY)	



Authorization for Use and Disclosure of Health Information (cont'd)

- VI. Communicate with you about your medication and treatment, including adherence materials, reminders, health and lifestyle tips, and product and other related information;
- VII. Provide you with the disease and medication education, and injection training by a LEQEMBI Companion Nurse Educator;
- VIII. Conduct surveys, data analytics, market research, quality assurance and improvement purposes, and other internal business activities related to the Program and Eisai products and programs; and
 - IX. Contact you via postal mail, email, phone, or text message at the number(s) you provide about the Program or any issues related to the Program.

By signing the authorization below, I authorize the uses and disclosures of my Health Information described above in Sections I-IX. I further authorize the use and disclosure of my Health Information to my Healthcare Providers, Insurers, government agencies, other assistance programs, caregivers, or legally authorized representatives that I designate for the foregoing purposes. By designating a specific caregiver or authorized representative, I am authorizing that individual to provide information regarding my insurance plans, financial status, and other information necessary to facilitate my participation in the Program.

I understand that:

- Once my Health Information is shared, it may no longer be protected by federal privacy laws and it could be disclosed to others. However, Eisai intends to use and share my Health Information only as described in this Authorization or as otherwise permitted by law.
- I may refuse to sign this Authorization, and choosing not to sign it will not change the way my Healthcare Providers or Insurers treat me, but I will not have access to the Program or its support offerings.
- My signed Authorization will remain in effect for 5 years or such shorter period required by state law.
- I may revoke this Authorization at any time by mailing a request to 2730 S. Edmonds Lane, Suite 300, Lewisville, TX 75067, faxing a request to 1-833-770-7017, or calling 1-833-453-7362. I also understand that revoking this Authorization will make it invalid with respect to uses and disclosures of my Health Information after the date my revocation letter is received, but that it will not invalidate uses and disclosures made in reliance upon the Authorization prior to that date.
- I am entitled to receive a copy of this Authorization.





Phone: 1-833-453-7362 | Fax: 1-833-770-7017 | M-F: 8 AM-8 PM ET

ent's name	DOB (MM/DD/YY	YY)
$\overset{ extsf{O}}{ extsf{v}}$ Authorization for Use a	nd Disclosure of Health Informatio	n (cont'd)
Signature required for LEQEMBI Companion er	nrollment	
Name of patient	Patient signature	 Date
Name of authorized representative	Authorized representative signature	 Date
	Relation to patient	

Consent to receive LEQEMBI marketing communications (OPTIONAL)

Yes. By checking this box, I consent to Eisai, its affiliates and service providers contacting me through emails and online platforms with reminders, education, lifestyle tips, and other resources relating to LEQEMBI and Alzheimer's disease generally. In doing so, I understand that Eisai may collect and use the information about me, some of which may be considered "sensitive" or "health data" and further share it with its service providers for Eisai marketing (e.g., product news and resources including LEQEMBI). I understand that I may withdraw my consent at any time by clicking the "unsubscribe" link at the bottom of Eisai emails or following the instructions on our "Your Choices and Rights" page (available here: https://us.eisai.com/privacy-policy/your-choices-and-rights). Email address is required.

LEQEMBI Infusion Temporary Supply Program terms and conditions

The Temporary Supply Program provides a temporary free supply of up to 75 days of LEQEMBI infusions for eligible, commercially insured patients new to LEQEMBI infusion therapy awaiting a final coverage determination from their insurance provider for 5 or more business days and the patient's provider has submitted a first-level appeal of the prior authorization denial. Patient must have a valid prescription for LEQEMBI infusion for an FDA-approved indication and meet certain financial need criteria. Not available for uninsured patients or patients enrolled in state and federal healthcare programs, including Medicare, Medicaid, Medigap, VA, DoD, or TRICARE. Eisai reserves the right to rescind, revoke, or amend this Program at any time without notice. To review complete terms and conditions, visit EisaiPatientSupport.com/LEQEMBI.

LEQEMBI Patient Assistance Program terms and conditions

The Patient Assistance Program for LEQEMBI provides free drug for eligible patients who meet financial need and insurance coverage criteria. Patient must have a valid prescription for LEQEMBI for an FDA-approved indication. Eisai reserves the right to rescind, revoke, or amend this Program at any time without notice. To review complete terms and conditions, visit EisaiPatientSupport.com/LEQEMBI.

LEQEMBI Patient Assistance and Temporary Supply Programs attestation

Signature required for LEQEMBI Infusion Temporary Supply Program and LEQEMBI Patient Assistance Program enrollment

I certify that all of the information provided in this application is complete and accurate. I understand that completing this form does not ensure that I will qualify for the LEQEMBI Patient Assistance Program ("PAP") or the Temporary Supply Program ("TSP") (together, the "Programs"). I understand that Program enrollment will terminate if LEQEMBI is no longer prescribed to me. I understand that during the Program enrollment period, I must receive all LEQEMBI doses through the Program only. I agree to notify and shall be responsible for notifying the LEQEMBI Companion program for LEQEMBI at 1-833-453-7362 immediately if anything changes with my LEQEMBI prescription, income, or my insurance coverage. I understand and agree that I will not seek reimbursement or credit from, or submit a claim for LEQEMBI provided through the Programs to any insurer, health plan, or government program (such as Medicare or Medicaid). I also understand and agree that I may not seek to have any part of the value of the LEQEMBI provided to me free of charge from the Programs count towards any applicable out-of-pocket spending calculations for drugs (eg, deductible, out-of-pocket cap, or True Out of Pocket ["TrOOP"] associated with my insurance). I understand that the provision of LEQEMBI as part of the Programs is not contingent on any future purchase of LEQEMBI.





Phone: 1-833-453-7362 | Fax: 1-833-770-7017 | M-F: 8 AM-8 PM ET

t's name	DOB (MM/DD/	YYYY)
(in whole or in part), including modification o	t at any time and without notice to me to modify and/or disc of eligibility criteria and immediate termination of assistance of this form and decline to be evaluated for the PAP and TSP.	
signing below, I authorize Eisai Inc. and its se information from my credit profile or other fir	nay be required in order for LEQEMBI Companion to assess rervice providers administering the PAP and TSP to obtain fron nancial information that Eisai needs to determine my financial documentation in a timely manner, if so requested.	m Experian Health the fin
Name of patient	Patient signature	 Date
Name of authorized representative	Authorized representative signature	Data
		Date

LEQEMBI Copay Assistance Program terms and conditions

Patient must be prescribed LEQEMBI for an FDA-approved indication. Patient must have private, commercial health insurance that provides coverage for LEQEMBI. The offer is not valid for patients enrolled in state and federal healthcare programs, including Medicare, Medicaid, Medigap, VA, DoD, or TRICARE, that cover outpatient care, including for physician-administered or prescription drugs, or otherwise cover LEQEMBI. The offer is not valid for uninsured or self-paying patients, or for LEQEMBI treatments reimbursed in full by any third-party payer. Patient must be 18 years or older. Patient must be a resident of, and product must be administered in, the United States or Puerto Rico.

Eisai Inc. will pay up to \$10,000 per calendar year toward an eligible patient's out-of-pocket costs for LEQEMBI, including deductibles, copays, and coinsurances. Eligible patients who participate in the Program may pay as little as \$0 out-of-pocket per date of treatment. Depending on the patient's insurance plan, patient could have additional financial liability for any amount over Eisai's maximum benefit. The offer is not valid for any other out-of-pocket costs, including medical administration charges. The LEQEMBI Copay Assistance Program will process eligible claims for patient out-of-pocket costs for LEQEMBI incurred for product administered up to 180 days prior to the date the patient is enrolled in the program. For patients prescribed LEQEMBI infusions, by enrolling in the program and accepting payment, provider agrees to put the value of the patient LEQEMBI Copay Assistance Program directly toward the patient's out-of-pocket costs for LEQEMBI Infusions only. Patient and provider/pharmacy agree not to seek reimbursement for any or all of the benefit received by the patient through the LEQEMBI Copay Assistance Program and are responsible for complying with all requirements to disclose to insurance carriers and third-party payers the benefit received from the LEQEMBI Copay Assistance Program. The offer may not be combined with any other discount, coupon, free trial, or offer. Federal law prohibits the selling, purchasing, trading, or counterfeiting of this offer. Void outside the USA and where prohibited by law. Eisai Inc. reserves the right to rescind, revoke, or amend this offer at any time without notice. The value of this offer is not contingent on any prior or future purchases. This offer is solely intended to provide savings on the purchase of LEQEMBI. This offer may not be accepted by all providers, pharmacies or alternate sites of care. The LEQEMBI Copay Assistance Program is not an insurance program. There will be no membership fees.

Additional Copay Assistance Program terms and conditions that apply to the LEQEMBI Infusion Copay Assistance Program ONLY: In order to be eligible for reimbursement under the LEQEMBI Copay Assistance Program, claims for LEQEMBI infusions must be submitted by provider to patient's private health insurance separately from other services and products. Additional instructions regarding required documentation in support of each claim will be provided by the program following confirmation of eligibility and enrollment. Upon enrollment in the program, each patient will be issued a 16-digit virtual debit card. By enrolling in this program, the patient is providing consent for the LEQEMBI Copay Assistance Program to provide payment information for any approved claims, in the form of the 16-digit virtual debit card number, directly to the provider or alternate site of care identified on this enrollment form to be applied directly to the patient's out-of-pocket costs for LEQEMBI infusions. If provider has already received payment from the patient for the patient's out-of-pocket cost for LEQEMBI infusions covered by the program, provider agrees to refund the amounts received back to the patient.





Phone: 1-833-453-7362 | Fax: 1-833-770-7017 | M-F: 8 AM-8 PM ET

nt's name	DOB (MM/DD/YYYY)
LEQEMBI Copay Assistance	patient attestation
Signature required for Copay Assistance	ent
	nat I will qualify for the LEQEMBI Copay Assistance Program. I have reac e LEQEMBI Copay Assistance Program, set forth on this enrollment forn
knowledge. I further certify (1) that I am r Medicaid, Medigap, VA, DoD, or TRICARE otherwise cover LEQEMBI; (2) that I have	he sections of the form completely, accurately, and to the best of my by federal or state subsidized healthcare program, including Medicare, atient care, including for physician-administered or prescription drugs, my current insurance coverage; and (3) that I will not seek reimbursements including from a flexible spending account, a healthcare savings
I agree to notify and shall be responsible longer meet the eligibility criteria for the	program administrator for the LEQEMBI Copay Assistance Program if I Assistance Program.
to provide payment information for appro-	rogram, I also provide consent for the LEQEMBI Copay Assistance Prograr e form of a 16-digit virtual debit card number, directly to the provider, Ilment form to be applied directly to my out-of-pocket costs for LEQEMBI
	Copay Assistance Program is limited to my out-of-pocket cost for of-pocket costs, including medical administration charges.
LEQEMBI Copay Assistance Program, inc	and without notice to me to modify and/or discontinue any or all of the on of eligibility criteria and immediate termination of assistance. ne to be considered for the LEQEMBI Copay Assistance Program.
Name of patient	Patient signature Date

Authorized representative signature

Relation to patient

Name of authorized representative

Date